Treatment of haematology     

FOI REFERENCE: 24286   FOI DATE: 7^th August 2024     

MYELOPROLIFERATIVE DISEASES

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?  

Name of medicine		Number patients treated
1.1 Fedratinib (Inrebic)		*
1.2 Momelotinib (Omjjara)		0
1.3 Ruxolitinib (Jakavi)		22
1.4 Hydroxycarbamide		242

Q2 How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?   

Diagnosis with ICD10 codes		Number patients treated
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3		46
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3		0
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3		136
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1		67

Q3.  How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?  

Name of medicine		Number patients treated
3.1 Fedratinib (Inrebic)		0
3.2 Momelotinib (Omjjara)		0
3.3 Ruxolitinib (Jakavi)		0
3.4 Hydroxycarbamide		0
3.5 Peginterferon Alfa-2a (Pegasys)		0
3.6 Ropeginterferon Alfa-2b (Besremi)		0
3.7 Epoetin alfa (Eprex, Binocrit)		0
3.8 Epoetin beta (NeoRecormon, Mircera)		0
3.9 Epoetin zeta (Retacrit)		0
3.10 Darbepoetin (Aranesp)		0
3.11 No active treatment		0
3.12 Allogeneic stem cell transplant		0

Q4. How many patients were treated with ruxolitinib (Jakavi) in combination with epoetin in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?  

Please include all types of epoetin – epoetin alfa, epoetin beta, epoetin zeta, darbepoetin alfa

Name of medicine		Number patients treated
4.0 Ruxolitinib (Jakavi) + epoetin		0

 NON HODGKIN LYMPHOMA (NHL) AND CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

 Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?  

Name of medicine		Number patients treated
5.1 Acalabrutinib (Calquence)		65
5.2 Ibrutinib (Imbruvica)		32
5.3 Pirtobrutinib (Jaypirca)		0
5.4 Venetoclax (Venclyxto)		*
5.5 Zanubrutinib (Brukinsa)		11

Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 – were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?  

Name of medicine		Number patients treated
6.1 Acalabrutinib (Calquence)		64
6.2 Ibrutinib (Imbruvica)		8
6.3 Pirtobrutinib (Jaypirca)		0
6.4 Venetoclax (Venclyxto)		*
6.5 Zanubrutinib (Brukinsa)		*

Q7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of monotherapy or combination		Number patients treated
7.1 Ibrutinib + venetoclax		*
7.2 Obinutuzumab + venetoclax		*
7.3 Acalabrutinib monotherapy / maintenance		64
7.4 Zanubrutinib monotherapy / maintenance		*
7.5 Ibrutinib monotherapy / maintenance		8
7.6 Venetoclax monotherapy		*
7.7 Venetoclax + rituximab		6

MANTLE CELL LYMPHOMA

 Q8. How many patients with Mantle Cell Lymphoma – ICD10 code = C831, C83.1 – were treated in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

		Number patients treated
8.0 Treated for Mantle Cell Lymphoma		0

Q8.1 How many patients with Mantle Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?  

Name of medicine		Number patients treated
8.1 MaxiCHOP + rituximab + high dose Cytarabine or NORDIC protocol		0
8.2 Stem Cell Transplant		0
8.3 Rituximab + bendamustine + cytarabine		0
8.4 Rituximab + bendamustine		0
8.5 Ibrutinib		0
8.6 Rituximab + CHOP, Rituximab + CVP or rituximab + other chemo		0
8.7 Acalabrutinib + rituximab + bendamustine		0

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018